ArticleThe AAPS journal2022

Risk Factors, Hyaluronidase Expression, and Clinical Immunogenicity of Recombinant Human Hyaluronidase PH20, an Enzyme Enabling Subcutaneous Drug Administration.

Marie A Printz et al.PubMed ↗Publisher ↗

No numbers read from the abstract.